TLR7 agonist 29

• Description:

  TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM) . TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC[1].

• UNSPSC:

  12352005

• Target:

  ADC Payload; IFNAR; PD-1/PD-L1; Toll-like Receptor (TLR)

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Smiles:

  NC1=C2C(N(CC3=CN=C(CNC4CCC4)C=C3)C(O)=N2)=NC(OCCCC)=N1

• Molecular Formula:

  C20H27N7O2

• Molecular Weight:

  397.47

• References & Citations:

  [1]Sega E, et al., Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells. Bioconjug Chem. 2025 Feb 13.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  TLR7

• CAS Number:

  [2275612-76-3]